½ðɳjs93252¼¯ÍÅ-¿ÆÑ§¼Ò·¢ÏÖE3·ºËØ»¯Á¬½ÓøCop1 ÔÚÖ×ÁöÃâÒßÖÎÁÆÖеÄ×÷ÓûúÖÆ
2026-01-13 12:32:59

¿ÆÑ§¼Ò·¢Ã÷E3·ºËØ»¯ÅþÁ¬Ã¸Cop1 ÓÚÖ×ÁöÃâÒßÒ½ÖÎÖеÄ×÷ÓûúÖÆ

ÈÕÆÚ£º2021-11-10 À´Àú£º±¾Õ¾ ¹©¸å£ºÏÖ´úҽѧÓë´óÖÚÎÀÉú´¦ ×÷ÕߣºÖÎÀíÔ± ÖÖ±ð£ºÒëÎÄ

½üÈÕ£¬ÃÀ¹úµ¤ÄÈ·¨²®°©Ö¢Ñо¿ÔºµÄÑо¿ÍŶӷ¢Ã÷Ö×Áöϸ°ûÖеÄE3·ºËØÅþÁ¬Ã¸Cop1£¨Èçϼò³Æ¡°Cop1¡±£©¾­Óɹý³Ìµ÷ÖÎÖ×Áö΢Çé¿öÖеÄÇ÷»¯Òò×ÓÅÅй¼°¾ÞÊÉϸ°û½þÈóÀ´Ó°ÏìÖ×ÁöÃâÒßÒ½Öι¦ÄÜ¡£¸ÃÑо¿ÓÚ¡¶Cell¡··¢±í£¬ÌâΪ¡°In vivo CRISPR screens identify the E3ligase Cop1 as a modulator of macrophage infiltration and cancer iÃÃÃÃunotherapytarget¡±¡£ ÃâÒ߲鳭µã×è¶Ï£¨iÃÃÃÃune checkpoint blockade, ICB£©ÁÆ·¨¿ÉÓÃÔÚÒ½ÖÎÈýÒõÐÔÈéÏÙ°©£¨triple-negative breast cancer, TNBC£©£¬µ«ÁÆÐ§ÓÐÏÞ¡£¸ÃÑо¿ÍŶӾ­Óɹý³ÌTNBCÄ£×ÓСÊóÑо¿·¢Ã÷£¬Cop1¾­Óɹý³Ìµ×ÎïTrib2ÅþÁ¬C/ebp¦ÄÂѰ׵ÄÂѰ×øÌ壬½ø¶ø½µ½âC/ebp¦ÄÂѰף»É¾³ýÁ˰©Ï¸°ûÖÐCop1¿ÉÏ÷¼õC/ebp¦ÄÂѰ׽µ½â£¬´Ó¶øÏ÷¼õ¾ÞÊÉϸ°ûÏà¸ÉÇ÷»¯Òò×ÓµÄÅÅйÒÔºÍÖ×Áö¾ÞÊÉϸ°ûµÄ½þÈó£¬ÖÕ¼«¼ÓÇ¿ICBÁÆÐ§¡£ ¸ÃÑо¿½á¹ûΪÍêÃÀTNBCÃâÒßÒ½ÖÎÒªÁìÌṩÁËеÄ˼Ð÷¡£ ×¢£º´ËÑо¿½á¹ûÕª×Ô¡¶Cell¡·£¬ÎÄÕÂÄÚÈݲ»´ú±í±¾ÍøÕ¾²»ÑŽðɳjs93252¼¯ÍÅ-µã¼°Ì¬¶È¡£ ÂÛÎÄÁ´½Ó£ºhttps://linkinghub.elsevier.com/retrieve/pii/S0092-8674(21)01053-9-½ðɳjs93252¼¯ÍÅ-



¸ü¶à²âÊÔÊý¾Ý¾´ÇëÆÚ´ý……